TC BioPharm Ltd TCBP

Healthcare Biotechnology

TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

NDAQ:TCBP - Post by User

TC BioPharm Ltd

Bullboard Posts

Next >>

Post by Desandanon Mar 16, 2022 7:28pm

23 Views

Post# 34520322

$TCBP News clips

A clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces positive interim data its Phase 1a/2b human study evaluating safety and tolerability of TCB-002, OmnImmune®, the Company's allogeneic unmodified gamma delta t-cell product, a novel therapeutic targeting the potential treatment of relapse/refractory Acute Myeloid Leukemia ("AML").

Bullboard Posts

Next >>

Canadian security stock unveils public offering and partner investment